Asterias Biotherapeutics, Inc. (AST)

[DeepDive]

Indeed, if you are looking into this investment, the Call is a must.

What is intriguing is that there is Stem Cell fatigue with investors: so many failed clinically of diluted shareholders to oblivion very few bother to follow the sector.

The science is working out and the story is being derisked.

I believe that we are not very far from inflection point in public perception: Stem Cell therapy - validated in the clinic- is going to get high valuations.